Download Review Article Guidelines
Download Research Article Guidelines
(Case and Research Submission Guidelines Below)
Applied Radiation Oncology is a board-reviewed clinical-review journal published quarterly by Anderson Publishing, Ltd. Each issue is delivered in print and electronically to 4000+ practicing radiation oncologists worldwide.
Materials submitted to Applied Radiation Oncology must be original work, and may not have been published elsewhere. Submissions should be review articles geared to radiation oncologists and should reflect practical everyday clinical applications, rather than research activity. Articles may pertain to clinical management, applications of a particular technology to treating an oncological condition, as well as administration, fiscal, technical, and/or medico-legal issues.
Please submit your review article to John Suh, MD, FASTRO, FACR, Chairman, Department of Radiation Oncology, Associate Director of Gamma Knife Radiosurgery, Brain Tumor and Neuro-oncology Center, Taussig Cancer Institute, 9500 Euclid Ave. / T28, Cleveland, OH 44195. Email: suhj@ccf.org.
The cover page should include the full title of the article as well as the following information:
For all copyrighted materials used in your manuscript, such as Figures and Tables, the author must include written permission attained from the Publisher (eg, Elsevier, McGraw-Hill) upon submitting the case to Applied Radiation Oncology. The assignment of rights to Anderson Publishing includes, but is not limited to, rights to edit, publish, reproduce, distribute copies, and publish in electronic form or other media. Authors retain the right to revise, adapt, prepare derivative works, present orally, or distribute the article, provided notice of copyright is given.
Upon acceptance we request that you provide us with DICOM image data sets for the key images. Please provide the DICOM data set as a ZIPPED file and upload the ZIPPED files labeled with the corresponding author's name to:
Questions should:
Example: “Which of the following presents as a chronic airspace disease on a chest radiograph?”
Cases should run from 750-1,000 words in length.
Please submit your case in MS Word format with images and figures included to: Sharon Breske, Managing Editor, Applied Radiation Oncology at email: sharon@appliedradiationoncology.com.
The cover page should include the full title of the article as well as the following information:
All tables must be cited in text, numbered in order of first appearance in the article (Table 1, Table 2, etc.). Indicate appropriate table title and define all abbreviations, symbols, and footnotes used.
Reference citations in the text must be numbered sequentially in order of first appearance in the text. Please do not list the references alphabetically. Reference numbers may be cited repeatedly in the text; however, all references must be cited at least once. Please use AMA format for references and overall style.
For all copyrighted materials used in your manuscript, such as Figures and Tables, the author must include written permission attained from the Publisher (eg, Elsevier, McGraw-Hill) upon submitting the case to Applied Radiation Oncology. The assignment of rights to Anderson Publishing includes, but is not limited to, rights to edit, publish, reproduce, distribute copies, and publish in electronic form or other media. Authors retain the right to revise, adapt, prepare derivative works, present orally, or distribute the article, provided notice of copyright is given.
Upon acceptance we request that you provide us with DICOM image data sets: For the key images, please provide the DICOM data set as a ZIPPED file and upload the ZIPPED files labeled with the corresponding author's name to:
Please submit your research article to John Suh, MD, FASTRO, FACR, Chairman, Department of Radiation Oncology, Associate Director of Gamma Knife Radiosurgery, Brain Tumor and Neuro-oncology Center, Taussig Cancer Institute, 9500 Euclid Ave. / T28, Cleveland, OH 44195. Email: suhj@ccf.org.
The cover page should include the full title of the article as well as the following information:
Provide a short overview of the research, including the objective and hypothesis, methods and materials, results, conclusions, and key words.
State the objectives and provide background, including a brief review of the literature. Discuss what experimental question the study aims to answer, and state the hypothesis. Briefly describe how the hypothesis was tested and how the results will contribute to radiation oncology.
Include a straightforward description of the methods used in the study, including enough detail so the work may be reproduced. References should be used for previously published methods, with relevant modifications described.
Results should be concise, presenting the experimental data.
Briefly provide an overview of the work. Summarize the most important findings and, if applicable, accept or reject the hypothesis. Identify the most interesting, significant findings and contrast them to other studies. Consider other works that address the topic and the how the work contributes to radiation oncology. Conclusions State the primary conclusions of the study.
All tables must be cited in text, numbered in order of first appearance in the article (Table 1, Table 2, etc.). Indicate appropriate table title and define all abbreviations, symbols, and footnotes used.
Reference citations in the text must be numbered sequentially in order of first appearance in the text. Please do not list the references alphabetically. Reference numbers may be cited repeatedly in the text; however, all references must be cited at least once. Please use AMA format for references and overall style.
For all copyrighted materials used in your manuscript, such as Figures and Tables, the author must include written permission attained from the Publisher (eg, Elsevier, McGraw-Hill) upon submitting the case to Applied Radiation Oncology. The assignment of rights to Anderson Publishing includes, but is not limited to, rights to edit, publish, reproduce, distribute copies, and publish in electronic form or other media. Authors retain the right to revise, adapt, prepare derivative works, present orally, or distribute the article, provided notice of copyright is given.
Upon acceptance we request that you provide us with DICOM image data sets for the key images. Please provide the DICOM data set as a ZIPPED file and upload the ZIPPED files labeled with the corresponding author's name to:
Authors must ensure that no part of their manuscript has been published or is under review by another publishing house. ARO only accepts original unpublished work. Portions of the manuscript presented at a conference as an abstract, poster, presentation or exhibit may be published with an acknowledgement of the disclosure. Authors must indicate any use of copyrighted material and provide permissions to reprint the material with their submission.
The order of authors listed in a manuscript should indicate level of contribution (first author listed is the lead author). All authors must have contributed substantially to the work with regard to its concept/design, writing and revisions, and approval. Authors must provide necessary referencing, and are responsible for a manuscript’s content and accuracy.
Authors should follow the “Recommendations for the Conduct, Reporting, Editing and Publication of Scholarly Requirements for Manuscripts” http://www.icmje.org/urm_main.html by the International Committee of Medical Journal Editors (ICMJE).
Applied Radiation Oncology follows the “Editorial Policy Statements” found at http://www.councilscienceeditors.org/resource-library/editorial-policies by the Council of Science Editors (CSE), which describes the rights and responsibilities of editors of peer-reviewed journals.
In general, ARO adheres to the “Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals (www.icmje.org) with regard to suspected scientific misconduct. Authors involved in ethical misconduct may be banned from submitting future manuscripts, and articles that violate ethical practices will be retracted. Ethical misconduct in publishing includes plagiarism, data falsification, duplicate publishing and inappropriate authorship (eg, article submission with author agreement, inclusion of authors who did not significantly contribute to the work, or exclusion of authors contributed extensively). ARO follows guidelines set forth by the Committee on Publication Ethics (COPE’s guidelines) in dealing with ethics allegations.
In order to comply with laws and regulations regarding the privacy/security of personal information, identifying details of patients should be omitted from all articles if they are not essential, and informed consent should be obtained if there is any doubt regarding patient anonymity. Informed consent for this purpose requires that a patient who is identifiable be shown the manuscript to be published. When obtained, informed consent will be indicated in the published article. If the authors do not have permission from the patient or appropriate party, they must remove personal information of those concerned in the article, illustrations and related materials; it is generally not sufficient to use eye bars or face-blurring techniques. If identifying characteristics are altered to protect anonymity, such as in genetic pedigrees, authors should provide assurance that alterations do not distort scientific meaning. Authors should also identify individuals who provide writing assistance, and disclose the funding source for this assistance.
Authors/researchers must ensure that the planning conduct and reporting of human research comply with the Helsinki Declaration (www.wma.net/policies-post/wma-declaration-of-helsinkiethical-principles-for-medical-research-involving-humansubjects/). Authors should secure approval to conduct research from an independent local, regional, or national review body such as an institutional review board, ethics committee, etc. If unsure whether the research complied with the Helsinki Declaration, the authors must explain the rationale for their approach and show that the review body approved any doubtful elements of the study.
Any animal experiments should comply with the ARRIVE guidelines and be carried out in accordance with the U.K. Animals (Scientific Procedures) Act, 1986 and associated guidelines, EU Directive 2010/63/EU for animal experiments, or the National Institutes of Health guide for the care and use of Laboratory animals (NIH Publications No. 8023, revised 1978). The manuscript should state that such guidelines have been met. Additional guidelines on animal research ethics are available from the International Association of Veterinary Editors’ Consensus Author Guidelines on Animal Ethics and Welfare (http://veteditors.org/ethicsconsensusguidelines.html).
ARO welcomes comments on all articles, and correspondence should be sent to Editor-in-Chief John Suh, MD, FASTRO, at suhj@ccf.org. ARO will provide relevant comments to authors of articles discussed in correspondence and will ask authors to respond to substantial criticisms of their work. Authors of correspondence should declare any competing or conflicting interests. Correspondence may be edited for length, grammatical correctness, and journal style. Alternatively, comments may be made online in the comment section of individual articles featured at www.appliedradiationoncology.com. Comments that are discourteous, inaccurate or irrelevant article will be removed at the editor’s discretion.
All review articles, case reports and research articles are reviewed by radiation oncologists and/or medical physicists on the ARO Review Panel whose expertise most closely matches the article topic. Reviews are double-blind and assess the practicality, originality, accuracy, presentation, usefulness and overall content of the manuscripts. Reviewers typically have 4-6 weeks to comment and recommend one of the following: reject, unacceptable/major revision, acceptable/minor revision, accept. Authors receive a summary of comments, which may include tracked changes; they must address each point when submitting corrections. The reviewers accept or reject revisions, or may ask for additional revisions until satisfied.
There are no fees for manuscript submission at this time.
Errors or important omissions made by authors or introduced by editors, production staff or printers will be corrected at the first opportunity. For print, this means providing a correction notice in the next available journal issue; online, this means correcting the error within the article in question as soon as possible. Corrections in print will be noted in the table of contents.
ARO follows the recommendations for peer reviewers as set forth in “Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals” by the International Committee of Medical Journal Editors (ICMJE). These recommendations state that because manuscripts submitted to journals are privileged communications, reviewers should keep manuscripts and the information they contain strictly confidential. Reviewers must not publicly discuss authors’ work and must not appropriate authors’ ideas before manuscript publication. Reviewers must not retain the manuscript for personal use and should destroy copies of manuscripts after submitting their reviews. Reviewers are expected to respond promptly to requests to review, and to submit reviews within the time agreed. Reviewers’ comments should be constructive, honest, and polite. Reviewers should declare their conflicts of interest and recuse themselves from the peer-review process if a conflict exists.
ARO follows the recommendations for advertising set forth by the ICMJE’s “Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals.” These recommendations state that advertisements should not be juxtaposed with editorial content on the same product and should be clearly identifiable as advertisements. Editors have full and final authority for approving print and online advertisements and for enforcing advertising policy. ARO will not carry advertisements for products proven to be seriously harmful to health, and will consider all criticisms of advertisements for publication. Advertisements are not related in any way to editorial decision making. Online advertisements are displayed at random vs. being linked to content or reader behavior. Types of advertisements are described in the ARO Media Planner at https://appliedradiationoncology.com/Advertise.
